KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Long-Term Deferred Tax: 2017-2019

Historic Long-Term Deferred Tax for Amneal Pharmaceuticals (AMRX) over the last 1 years, with Jun 2019 value amounting to $391.9 million.

  • Amneal Pharmaceuticals' Long-Term Deferred Tax rose 4.86% to $391.9 million in Q2 2019 from the same period last year, while for Jun 2019 it was $391.9 million, marking a year-over-year increase of 4.86%. This contributed to the annual value of $373.2 million for FY2018, which is 41454.45% up from last year.
  • As of Q2 2019, Amneal Pharmaceuticals' Long-Term Deferred Tax stood at $391.9 million, which was up 2.33% from $382.9 million recorded in Q1 2019.
  • Amneal Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $391.9 million during Q2 2019, with a 5-year trough of $898,000 in Q4 2017.
  • For the 3-year period, Amneal Pharmaceuticals' Long-Term Deferred Tax averaged around $314.8 million, with its median value being $373.4 million (2018).
  • Data for Amneal Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY spiked of 41,454.45% (in 2018) over the last 5 years.
  • Over the past 3 years, Amneal Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at $898,000 in 2017, then surged by 41,454.45% to $373.2 million in 2018, then rose by 4.86% to $391.9 million in 2019.
  • Its last three reported values are $391.9 million in Q2 2019, $382.9 million for Q1 2019, and $373.2 million during Q4 2018.